U.S., Aug. 11 -- ClinicalTrials.gov registry received information related to the study (NCT07755683) titled 'Effect of Daprodustat and Epoetin Alpha on Anemia in Patients Not Undergoing Dialysis' on Aug. 04.
Brief Summary: Anemia in CKD patients is mainly attributed to impaired kidney being unable to adequately respond to hypoxia and/or anaemia by inducing erythropoietin (EPO) production iron disorders, blood loss, shortened erythrocyte survival time and inflammation. High mortality among patients with advanced renal failure is directly related to the severity of anemia and hypoalbuminemia, particularly within the first six months.4, 5 Currently, the main treatment modalities for anemia in CKD include injections of erythropoiesis stimulati...